The impact of acute-phase reaction on mortality and re-fracture after zoledronic acid in hospitalized elderly osteoporotic fracture patients
ConclusionsOur findings suggested a potential association between the occurrence of APR and increased mortality risk. An initial dose of ZOL following orthopedic surgery was found to be protective against re-fracture in older patients with OPFs. (Source: Osteoporosis International)
Source: Osteoporosis International - May 29, 2023 Category: Orthopaedics Source Type: research
Safety of Inpatient Zoledronic Acid in the Immediate Post-Fracture Setting
CONCLUSIONS: IP-ZA along with standing multiple-doses-per-day acetaminophen, administered to patients in the immediate post-fracture period, is not associated with significant acute adverse effects.PMID:37227016 | DOI:10.1210/clinem/dgad295 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - May 25, 2023 Category: Endocrinology Authors: WuQiang Fan Benjamin Z Leder Michael Mannstadt Thuan V Ly Esteban Franco-Garcia Marcy B Bolster Source Type: research
Safety of Inpatient Zoledronic Acid in the Immediate Post-Fracture Setting
CONCLUSIONS: IP-ZA along with standing multiple-doses-per-day acetaminophen, administered to patients in the immediate post-fracture period, is not associated with significant acute adverse effects.PMID:37227016 | DOI:10.1210/clinem/dgad295 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - May 25, 2023 Category: Endocrinology Authors: WuQiang Fan Benjamin Z Leder Michael Mannstadt Thuan V Ly Esteban Franco-Garcia Marcy B Bolster Source Type: research
Granulocyte-colony stimulating factor producing cervical cancer with elevated levels of parathyroid hormone-related protein: a case report and literature review
AbstractSystemic effects associated with hormones and cytokines secreted by tumor cells can cause paraneoplastic syndrome. Leukemoid reactions and hypercalcemia are relatively common manifestations of paraneoplastic syndrome. Here, we describe the case of a 90-year-old woman who presented with leukocytosis and hypercalcemia and was diagnosed with granulocyte-colony stimulating factor (G-CSF)-producing cervical cancer with elevated levels of parathyroid hormone-related protein (PTHrP). The patient visited our hospital complaining of general fatigue and anorexia. On admission, she presented with marked leukocytosis, hypercal...
Source: CEN Case Reports - May 25, 2023 Category: Urology & Nephrology Source Type: research
< em > In vitro < /em > and < em > in vivo < /em > effects of zoledronic acid on senescence and senescence-associated secretory phenotype markers
Aging (Albany NY). 2023 May 7;15. doi: 10.18632/aging.204701. Online ahead of print.ABSTRACTIn addition to reducing fracture risk, zoledronic acid has been found in some studies to decrease mortality in humans and extend lifespan and healthspan in animals. Because senescent cells accumulate with aging and contribute to multiple co-morbidities, the non-skeletal actions of zoledronic acid could be due to senolytic (killing of senescent cells) or senomorphic (inhibition of the secretion of the senescence-associated secretory phenotype [SASP]) actions. To test this, we first performed in vitro senescence assays using human lun...
Source: Aging - May 8, 2023 Category: Biomedical Science Authors: Parinya Samakkarnthai Dominik Saul Lei Zhang Zaira Aversa Madison L Doolittle Jad G Sfeir Japneet Kaur Elizabeth J Atkinson James R Edwards Graham G Russell Robert J Pignolo James L Kirkland Tamar Tchkonia Laura J Niedernhofer David G Monroe Nathan K Lebr Source Type: research
< em > In vitro < /em > and < em > in vivo < /em > effects of zoledronic acid on senescence and senescence-associated secretory phenotype markers
Aging (Albany NY). 2023 May 7;15. doi: 10.18632/aging.204701. Online ahead of print.ABSTRACTIn addition to reducing fracture risk, zoledronic acid has been found in some studies to decrease mortality in humans and extend lifespan and healthspan in animals. Because senescent cells accumulate with aging and contribute to multiple co-morbidities, the non-skeletal actions of zoledronic acid could be due to senolytic (killing of senescent cells) or senomorphic (inhibition of the secretion of the senescence-associated secretory phenotype [SASP]) actions. To test this, we first performed in vitro senescence assays using human lun...
Source: Aging - May 8, 2023 Category: Biomedical Science Authors: Parinya Samakkarnthai Dominik Saul Lei Zhang Zaira Aversa Madison L Doolittle Jad G Sfeir Japneet Kaur Elizabeth J Atkinson James R Edwards Graham G Russell Robert J Pignolo James L Kirkland Tamar Tchkonia Laura J Niedernhofer David G Monroe Nathan K Lebr Source Type: research
< em > In vitro < /em > and < em > in vivo < /em > effects of zoledronic acid on senescence and senescence-associated secretory phenotype markers
Aging (Albany NY). 2023 May 7;15. doi: 10.18632/aging.204701. Online ahead of print.ABSTRACTIn addition to reducing fracture risk, zoledronic acid has been found in some studies to decrease mortality in humans and extend lifespan and healthspan in animals. Because senescent cells accumulate with aging and contribute to multiple co-morbidities, the non-skeletal actions of zoledronic acid could be due to senolytic (killing of senescent cells) or senomorphic (inhibition of the secretion of the senescence-associated secretory phenotype [SASP]) actions. To test this, we first performed in vitro senescence assays using human lun...
Source: Aging - May 8, 2023 Category: Biomedical Science Authors: Parinya Samakkarnthai Dominik Saul Lei Zhang Zaira Aversa Madison L Doolittle Jad G Sfeir Japneet Kaur Elizabeth J Atkinson James R Edwards Graham G Russell Robert J Pignolo James L Kirkland Tamar Tchkonia Laura J Niedernhofer David G Monroe Nathan K Lebr Source Type: research
Comparability of Osteoporosis Treatment Groups Among Female Medicare Beneficiaries in the United States
ABSTRACTIt is often difficult to obtain valid estimates of comparative treatment effectiveness and safety owing to differences across patient populations taking different medications in the real world. One approach for assessing comparability between treatment groups in effectiveness studies is to use negative control outcomes (NCOs). NCOs share similar sources of bias with the primary outcomes but have no plausible causal relationship to the treatment of interest. Observing differences in the risk of NCOs thus provides evidence for residual confounding between groups. This retrospective study assessed the comparability of...
Source: Journal of Bone and Mineral Research - May 4, 2023 Category: Orthopaedics Authors: Min Kim,
Tzu ‐Chieh Lin,
Tarun Arora,
Hong Zhao,
Akhila Balasubramanian,
Robert Kees Stad,
James O'Kelly,
Leslie Spangler,
Brian D. Bradbury,
Jeffrey R. Curtis Tags: Research Article Source Type: research
Refracture risk and all-cause mortality after vertebral fragility fractures: Anti-osteoporotic medications matter
CONCLUSION: In addition to fracture prevention, anti-osteoporotic treatments for patients with vertebral fractures were associated with a reduction in mortality. A longer duration of treatment and the use of long-acting drugs was also associated with lower mortality.PMID:37120337 | DOI:10.1016/j.jfma.2023.04.004 (Source: J Formos Med Assoc)
Source: J Formos Med Assoc - April 29, 2023 Category: General Medicine Authors: Ta-Wei Tai Yi-Lun Tsai Chien-An Shih Chia-Chun Li Yin-Fan Chang Chun-Feng Huang Tien-Tsai Cheng Jawl-Shan Hwang Tsung-Hsueh Lu Chih-Hsing Wu Source Type: research
Refracture risk and all-cause mortality after vertebral fragility fractures: Anti-osteoporotic medications matter
CONCLUSION: In addition to fracture prevention, anti-osteoporotic treatments for patients with vertebral fractures were associated with a reduction in mortality. A longer duration of treatment and the use of long-acting drugs was also associated with lower mortality.PMID:37120337 | DOI:10.1016/j.jfma.2023.04.004 (Source: J Formos Med Assoc)
Source: J Formos Med Assoc - April 29, 2023 Category: General Medicine Authors: Ta-Wei Tai Yi-Lun Tsai Chien-An Shih Chia-Chun Li Yin-Fan Chang Chun-Feng Huang Tien-Tsai Cheng Jawl-Shan Hwang Tsung-Hsueh Lu Chih-Hsing Wu Source Type: research
Refracture risk and all-cause mortality after vertebral fragility fractures: Anti-osteoporotic medications matter
CONCLUSION: In addition to fracture prevention, anti-osteoporotic treatments for patients with vertebral fractures were associated with a reduction in mortality. A longer duration of treatment and the use of long-acting drugs was also associated with lower mortality.PMID:37120337 | DOI:10.1016/j.jfma.2023.04.004 (Source: J Formos Med Assoc)
Source: J Formos Med Assoc - April 29, 2023 Category: General Medicine Authors: Ta-Wei Tai Yi-Lun Tsai Chien-An Shih Chia-Chun Li Yin-Fan Chang Chun-Feng Huang Tien-Tsai Cheng Jawl-Shan Hwang Tsung-Hsueh Lu Chih-Hsing Wu Source Type: research
Refracture risk and all-cause mortality after vertebral fragility fractures: Anti-osteoporotic medications matter
CONCLUSION: In addition to fracture prevention, anti-osteoporotic treatments for patients with vertebral fractures were associated with a reduction in mortality. A longer duration of treatment and the use of long-acting drugs was also associated with lower mortality.PMID:37120337 | DOI:10.1016/j.jfma.2023.04.004 (Source: J Formos Med Assoc)
Source: J Formos Med Assoc - April 29, 2023 Category: General Medicine Authors: Ta-Wei Tai Yi-Lun Tsai Chien-An Shih Chia-Chun Li Yin-Fan Chang Chun-Feng Huang Tien-Tsai Cheng Jawl-Shan Hwang Tsung-Hsueh Lu Chih-Hsing Wu Source Type: research
Paget ’s disease: a review of the epidemiology, etiology, genetics, and treatment
Paget’s disease of bone (PDB) is the second most prevalent metabolic bone disorder worldwide, with a prevalence rate of 1.5%–8.3%. It is characterized by localized areas of accelerated, disorganized, and excessive bone production and turnover. Typically, PDB develops in the later stages of life, particularly in the late 50s, and affects men more frequently than women. PDB is a complex disease influenced by both genetic and environmental factors. PDB has a complex genetic basis involving multiple genes, with SQSTM1 being the gene most frequently associated with its development. Mutations affecting the UBA domain of SQST...
Source: Frontiers in Genetics - April 26, 2023 Category: Genetics & Stem Cells Source Type: research
Identifying therapeutic biomarkers of zoledronic acid by metabolomics
In conclusion, mevalonate, PHP, LHP, and 4-VPS are candidate therapeutic markers of ZOL. The pharmacological effect of ZOL likely occurs through inhibition of the PI3K-AKT signaling pathway. (Source: Frontiers in Pharmacology)
Source: Frontiers in Pharmacology - April 25, 2023 Category: Drugs & Pharmacology Source Type: research
